Valeo Financial Advisors, LLC - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 409 filers reported holding CRISPR THERAPEUTICS AG in Q3 2023. The put-call ratio across all filers is 1.08 and the average weighting 0.1%.

Quarter-by-quarter ownership
Valeo Financial Advisors, LLC ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$473,236
+20.5%
10,426
+49.0%
0.02%
+22.2%
Q2 2023$392,755
-7.2%
6,996
-25.2%
0.02%
-10.0%
Q1 2023$423,262
+47.8%
9,358
+32.8%
0.02%
+25.0%
Q4 2022$286,379
-35.1%
7,045
+4.4%
0.02%
-42.9%
Q3 2022$441,000
-24.0%
6,747
-29.3%
0.03%
-22.2%
Q2 2022$580,000
+3.8%
9,547
+7.2%
0.04%
+28.6%
Q1 2022$559,000
-1.1%
8,909
+19.5%
0.03%
-9.7%
Q4 2021$565,000
-16.4%
7,458
+23.5%
0.03%
-20.5%
Q3 2021$676,000
-26.2%
6,038
+6.8%
0.04%
-30.4%
Q2 2021$916,000
+32.8%
5,656
-0.1%
0.06%
+75.0%
Q1 2021$690,000
+20.6%
5,661
+51.5%
0.03%
+10.3%
Q4 2020$572,000
+75.5%
3,737
-4.2%
0.03%0.0%
Q3 2020$326,000
+14.8%
3,902
+0.9%
0.03%
+11.5%
Q2 2020$284,000
+667.6%
3,869
+381.8%
0.03%
+550.0%
Q1 2020$37,000
-19.6%
803
+7.1%
0.00%0.0%
Q4 2019$46,000
+76.9%
750
+17.2%
0.00%
+33.3%
Q3 2019$26,000
-23.5%
640
-11.7%
0.00%
-25.0%
Q2 2019$34,000
+30.8%
7250.0%0.00%
+33.3%
Q1 2019$26,000
+116.7%
725
+71.4%
0.00%
+50.0%
Q4 2018$12,0000.0%423
+11.6%
0.00%0.0%
Q3 2018$12,000
+200.0%
379
+345.9%
0.00%
+100.0%
Q2 2018$4,000
-20.0%
85
-19.0%
0.00%0.0%
Q1 2018$5,000
+66.7%
105
-19.2%
0.00%
Q4 2017$3,000
+200.0%
130
+85.7%
0.00%
Q3 2017$1,000700.00%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q3 2023
NameSharesValueWeighting ↓
Versant Venture Management, LLC 498,558$31,294,00031.24%
NEA Management Company, LLC 1,590,002$365,593,00010.56%
Ariose Capital Management Ltd 37,900$2,379,0009.30%
ARK Investment Management 9,404,071$590,294,0002.46%
NIA IMPACT ADVISORS, LLC 80,082$5,027,0002.44%
Nikko Asset Management Americas, Inc. 4,619,747$291,044,0002.14%
PLUSTICK MANAGEMENT LLC 50,000$3,139,0001.98%
Integral Health Asset Management, LLC 120,000$7,532,0001.96%
Valiant Capital Management, L.P. 240,683$15,108,0001.73%
Deuterium Capital Management, LLC 18,000$1,130,0001.45%
View complete list of CRISPR THERAPEUTICS AG shareholders